Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. reports developments in its global medical cannabis business, including product launches, brand expansion and regulated-market activity across Canada, Europe, Australia and New Zealand. The company serves medical and consumer cannabis markets through brands such as Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler, with GMP-certified manufacturing facilities in Canada and Germany.
Recurring announcements cover new formats such as dried flower, pre-rolls, pastilles and resin cartridges; operating and financial results; international market engagement; capital actions; and governance updates. Aurora's news also reflects its medical-first strategy and use of a global manufacturing network to supply regulated cannabis markets.
Aurora Cannabis (NASDAQ:ACB) reported fiscal 2026 results, highlighting record annual global medical cannabis net revenue1 of $288.6 million, up 18% year over year, and record annual Adjusted EBITDA1 of $53.8 million, up 32%.
The company ended Q4 2026 with total net revenue1 of $84.8 million, medical cannabis net revenue1 of $77.1 million, Adjusted EBITDA1 of $9.2 million, and approximately $164.7 million in cash, short-term investments and cash equivalents2 with no debt. Aurora completed a $26.5 million acquisition of Safari Flower Company, adding a 59,000 square foot EU-GMP indoor cultivation and manufacturing facility, and divested its 50.1% stake in Bevo. For fiscal 2027, Aurora expects lower total net revenue1, adjusted gross margins1 in the mid to high 50% range, broadly stable Adjusted SG&A1, and lower annual Adjusted EBITDA1 versus fiscal 2026.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB) highlighted expanded support for Veteran communities across Canada through its Strains for Heroes program as of June 2, 2026.
Aurora donates 5% of net profits from Strains for Heroes annually to Veteran-focused organizations, up to C$200,000, backing food security, mental health, leadership and community initiatives.
Aurora Cannabis (NASDAQ: ACB) will host a fourth quarter and fiscal year 2026 investor conference call on Thursday, June 11, 2026, at 8:00 a.m. Eastern / 6:00 a.m. Mountain. Financial results will be released before market open that same day.
Executive Chairman and CEO Miguel Martin and CFO Simona King will lead the call and Q&A. A webcast link is available via Aurora’s investor relations website under Events.
Aurora Cannabis (NASDAQ: ACB) received Canadian Plant Breeders' Rights for two proprietary cannabis cultivars developed at its Aurora Coast research facility. The grant covers SOT20R07-007 (Farm Gas) and SOT20R07-005 (Driftwood Diesel), giving Aurora exclusive rights to grow, propagate and sell products from these varieties.
Both cultivars are core medical products in Germany, Poland, the UK, Canada and Australia. According to Aurora, Plant Breeders' Rights protect its proprietary genetics, support ongoing research and innovation, and, together with recent European protections, strengthen its global competitive position in medical cannabis.
Aurora (NASDAQ: ACB) is expanding its global medical cannabis portfolio with scaled product launches across Canada, Germany, Poland, Australia and other regulated markets between now and June.
New formats include dried flower, pre-rolls and pastilles, with cultivar-specific potencies (THC up to 29%) and multi-compound pastilles. Aurora cites its GMP-certified manufacturing network to support reliable international supply.
Aurora Cannabis (NASDAQ: ACB) acquired Safari Flower Company for aggregate consideration of $26.5 million to expand EU GMP cultivation and manufacturing capacity. The 59,000 sq ft facility will supply EU GMP flower to key markets including Germany, Australia, Poland and the UK.
The deal included issuance of 2,417,180 common shares, a $15 million cash payment on closing and a contingent $2 million cash payment. Aurora expects positive Adjusted EBITDA contributions in fiscal 2027 with additional benefits in 2028 as assets are optimized.
Aurora (NASDAQ: ACB) was named to The Globe and Mail's 2026 Report on Business Women Lead Here list for the second consecutive year on March 30, 2026. Aurora is one of 85 companies on the list and reports 50% female executive leadership.
The recognition highlights Aurora's stated commitment to inclusive executive leadership, talent development, and sustained representation; the list appears in the April 2026 issue of Report on Business magazine and online.
Aurora (NASDAQ: ACB) will participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CFO Simona King will join a fireside chat and investor meetings to discuss international leadership and manufacturing trends in medical cannabis.
Webcast registration is available on the company's Investor Info page and a replay will be accessible for approximately 90 days. The company also announced completion of the previously disclosed Bevo transaction dated February 4, 2026.
Aurora (NASDAQ: ACB) will ring the Nasdaq closing bell on Wednesday, February 18, 2026 at Nasdaq MarketSite in Times Square. The ceremony begins with a live broadcast at 3:45 p.m. ET and the bell will ring at 4:00 p.m. ET.
CEO and Executive Chairman Miguel Martin will lead the event alongside board and executive representatives to highlight Aurora's medical-first, global cannabis strategy and progress in international markets.
Aurora (NASDAQ: ACB) is expanding its medical cannabis portfolio in Australia and New Zealand, launching multiple THC flower products in New Zealand and four resin cartridges in Australia on Feb 11, 2026. Products use Aurora proprietary genetics and are manufactured at EU‑GMP and TGA‑GMP certified facilities in Canada.
The New Zealand roll‑out includes Big Wave, Night Ride, and Half Moon (Q1 FY27). Australia debuts Chemango Kush, Cosmic Cream, Lunar Express and Soul Train Haze, reinforcing the company’s regional growth focus.